In a statement, Brazil’s health ministry said, it will be signing a non-binding letters of intent to buy coronavirus vaccines from four companies as well as from Russia’s sovereign wealth fund; these purchases will be subject to the approval of the nation’s regulators.

Last week, officials from Brazil’s health ministry met with representatives of India’s Bharat Biotech, Pfizer Inc, Janssen, a unit of Johnson & Johnson, the Russian Direct Investment Fund, and Moderna Inc, towards negotiating such purchases, The ministry’s legal and technical departments are now in the process of analyzing the documents presented by these five entities to determine the best way to purchase the vaccines at “the opportune moment.”

According to officials, the Brazilian government already has contracts in place which guarantees access to 142,900,000 coronavirus vaccine doses – sufficient to immunize at least a third of Brazil’s population.

While the Brazilian government has placed a supply contract with AstraZeneca PLC for its candidate of the coronavirus vaccine, local authorities have also signed a deal with China’s Sinovac Biotech Ltd to test and produce a vaccine locally.

Incidentally, Brazilian President Jair Bolsonaro, has dismissed the Chinese candidate of the coronavirus vaccine as untrustworthy.

Categories: Creativity, Economy & Finance, Entrepreneurship, HR & Organization, Regulations & Legal, Strategy, Sustainability

Tags: approval, AstraZeneca Plc, Bharat Biotech, Brazil, Brazilian, buy, coronavirus vaccines, health ministry, immunize, India, Janssen, Johnson & Johnson, letters of intent, Moderna Inc, non binding, Pfizer Inc, purchase, regulators, Russian Direct Investment Fund